Rafferty Asset Management, LLC Bluebird Bio, Inc. Transaction History

Rafferty Asset Management, LLC

$28.9 Billion
Q3 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$0.91 - $1.75 $1.2 Million - $2.31 Million	-1,317,237 Reduced 92.38%	108,636 $139,000
Q4 2023 Feb 13, 2024	SELL	$1.32 - $4.83 $86,510 - $316,548	-65,538 Reduced 4.39%	1,425,873 $1.97 Million
Q3 2023 Nov 13, 2023	SELL	$3.02 - $4.05 $1.05 Million - $1.4 Million	-346,051 Reduced 18.83%	1,491,411 $4.53 Million
Q2 2023 Aug 11, 2023	BUY	$2.79 - $5.03 $359,963 - $648,965	129,019 Added 7.55%	1,837,462 $6.05 Million
Q1 2023 May 11, 2023	BUY	$3.14 - $8.22 $1.71 Million - $4.48 Million	545,280 Added 46.88%	1,708,443 $5.43 Million
Q4 2022 Feb 13, 2023	BUY	$5.77 - $8.49 $1.11 Million - $1.63 Million	192,579 Added 19.84%	1,163,163 $8.05 Million
Q3 2022 Nov 14, 2022	BUY	$3.75 - $7.39 $2.66 Million - $5.23 Million	708,323 Added 270.08%	970,584 $6.14 Million
Q2 2022 Aug 12, 2022	SELL	$2.94 - $5.23 $2.11 Million - $3.75 Million	-716,861 Reduced 73.21%	262,261 $1.09 Million
Q1 2022 May 13, 2022	BUY	$4.07 - $10.6 $1.59 Million - $4.14 Million	390,594 Added 66.37%	979,122 $4.75 Million
Q4 2021 Feb 10, 2022	BUY	$8.96 - $16.31 $3.71 Million - $6.76 Million	414,254 Added 237.7%	588,528 $5.88 Million
Q3 2021 Nov 10, 2021	BUY	$11.24 - $21.0 $1.05 Million - $1.97 Million	93,739 Added 116.4%	174,274 $3.33 Million
Q2 2021 Aug 10, 2021	SELL	$18.04 - $22.09 $2.29 Million - $2.8 Million	-126,685 Reduced 61.14%	80,535 $2.58 Million
Q1 2021 May 10, 2021	BUY	$16.59 - $33.89 $2.78 Million - $5.67 Million	167,448 Added 421.02%	207,220 $6.25 Million
Q4 2020 Feb 10, 2021	SELL	$27.5 - $37.92 $29,535 - $40,726	-1,074 Reduced 2.63%	39,772 $1.72 Million
Q3 2020 Nov 13, 2020	BUY	$34.44 - $43.75 $892,064 - $1.13 Million	25,902 Added 173.33%	40,846 $2.2 Million
Q2 2020 Aug 07, 2020	BUY	$27.12 - $45.97 $265,830 - $450,597	9,802 Added 190.63%	14,944 $912,000
Q1 2020 May 15, 2020	SELL	$26.16 - $63.5 $1.01 Million - $2.45 Million	-38,570 Reduced 88.24%	5,142 $236,000
Q4 2019 Feb 10, 2020	SELL	$46.96 - $61.67 $851,056 - $1.12 Million	-18,123 Reduced 29.31%	43,712 $3.84 Million
Q3 2019 Nov 14, 2019	BUY	$59.47 - $93.1 $1.18 Million - $1.84 Million	19,811 Added 47.14%	61,835 $5.68 Million
Q2 2019 Aug 09, 2019	BUY	$75.84 - $105.21 $477,867 - $662,928	6,301 Added 17.64%	42,024 $5.35 Million
Q1 2019 May 15, 2019	BUY	$64.44 - $104.11 $2.3 Million - $3.72 Million	35,723 New	35,723 $5.62 Million

Others Institutions Holding BLUE

# of Institutions

151

Shares Held

63.4M

Call Options Held

264K

Put Options Held

428K

Black Rock Inc. New York, NY

15.4M
Shares

$5.4 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

10.5M
Shares

$3.67 Million
0.0% of portfolio
Geode Capital Management, LLC Boston, MA

4.68M
Shares

$1.64 Million
0.0% of portfolio
Pictet Asset Management Sa Geneva 73, V8

4.67M
Shares

$1.63 Million
0.02% of portfolio
State Street Corp Boston, MA

3.84M
Shares

$1.34 Million
0.0% of portfolio

View Full List

About bluebird bio, Inc.

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $27M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

More about BLUE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.

Account